Mepolizumab as induction therapy in severe eosinophilic granulomatosis with polyangiitis

Med Clin (Barc). 2024 Oct 18;163(7):370-371. doi: 10.1016/j.medcli.2024.03.023. Epub 2024 Jun 8.

[Article in English, Spanish]

Authors

Helena Codes-Méndez¹, Patricia Moya-Alvarado², Héctor Corominas³

Affiliations

¹ Servicio de Reumatología, Hospital de la Santa Creu i Sant Pau, Barcelona, España.
² Servicio de Reumatología, Hospital de la Santa Creu i Sant Pau, Barcelona, España; Universitat Autònoma de Barcelona, Bellaterra, España. Electronic address: pmoyaa@santpau.cat.
³ Servicio de Reumatología, Hospital de la Santa Creu i Sant Pau, Barcelona, España; Universitat Autònoma de Barcelona, Bellaterra, España.

PMID: 38853068
DOI: 10.1016/j.medcli.2024.03.023

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antibodies, Monoclonal, Humanized* / therapeutic use
Female
Granulomatosis with Polyangiitis* / complications
Granulomatosis with Polyangiitis* / drug therapy
Humans
Induction Chemotherapy
Male
Middle Aged

Substances

mepolizumab
Antibodies, Monoclonal, Humanized